Introduction
Hepatocellular carcinoma (HCC) is one of the most common neoplasms worldwide. Estimates of global incidence and mortality per year range between 400 000 and 1 million cases. The highest HCC incidence occurs in Sub-Saharan Africa and Southeast Asia (the incidence in Taiwan is 150 cases per 100 000 population per annum). Intermediate incidence regions include Eastern and Southern Europe, the Middle East, and South America [1] [2] [3] . Although HCC occurs less frequently in Northern Europe and the US, incidence in the US has increased dramatically in recent years, largely because of the prevalence of chronic hepatitis C (HCV) infection (estimated at nearly 4 million cases in the US) [4] . HCC occurs most frequently in patients with cirrhosis commonly due to chronic infection with HBV and HCV and longstanding alcohol abuse [1, 5] . Less common causes include autoimmune hepatitis, primary biliary cirrhosis, hemochromatosis and aflatoxin exposure.
Curative therapy for HCC is feasible for patients presenting with limited disease (unilobar tumors with absence of major vascular invasion or metastasis); these treatments include surgical resection, liver transplantation, alcohol injection and radiofrequency ablation. However, only 10-30% of patients diagnosed with HCC are eligible for such therapies, predominantly because of advanced tumor at presentation. HCC recurrence is common following surgical resection (and other potentially curative treatment), with 5-year survival following surgery as low as 30% in some series [6, 7] . Hence, the overwhelming majority of HCC patients are candidates for medical therapy at some point during the course of disease [8] .
Purpose of review
There exists limited consensus regarding therapeutic standards-of-care in unresectable HCC. Hepatic artery embolization is frequently undertaken at centers with experience in HCC treatment. However, many HCC patients are not candidates for embolization-based therapy (because of limited hepatic function, advanced hepatic tumor or metastatic disease). Although many HCC clinical trials have not demonstrated therapy to be efficacious, some of the more recently published investigations suggest that treatment may confer survival and quality-of-life benefit [9] . Because of the absence of consensus regarding management of unresectable HCC, because of interesting results reported since the publication of prior comprehensive reviews and because many randomized studies could not be included in recent meta-analyses, we reviewed randomized trials in unresectable HCC [10] [11] [12] .
Methods
A Medline search was performed through December 2002 using the MeSH term liver neoplasms, and limiting the results to randomized controlled trials and publications in English. The Pubmed search terminology was: ((''liver neoplasms'' [MeSH Terms] AND Randomized Controlled Trials [ptyp]) AND English [Lang]). The MeSH term carcinoma, hepatocellular was not used because it is subordinate to liver neoplasms and its inclusion in the search strategy did not change the result. The Medline search identified 405 articles. Earlier review papers and textbook chapters were also evaluated [10, 13] .
Medline search results were reviewed independently by two co-authors (discrepancies were resolved by consensus). Articles were excluded from subsequent review if they did not address HCC (e.g. metastases from colon cancer), did not test a therapeutic intervention (e.g. prevention of HCC), were limited to supportive care (i.e. no anticancer treatment, e.g. management of esophageal varices), did not include prospectively randomized data or included preliminary data without reporting on therapeutic impact upon survival. If the information from Medline (i.e. titles, abstracts, keywords, etc.) did not permit exclusion, the full publication was reviewed in a subsequent step. Articles were further divided into three groups as follows: (i) neo-adjuvant and adjuvant trials in surgically resectable HCC (this was the subject of our recent review) [14] , (ii) hepatic arterial embolization and embolization-based therapies in unresectable HCC (Part I of this report), and (iii) systemic and local nonembolization-based therapies in unresectable HCC (Part II of this report).
Results
In total, 406 Medline citations were identified via the search strategy described above. Of these citations, 279 were readily identified as pertaining to subjects not within the purview of this paper (i.e. involving diseases other than HCC, not investigating anti-HCC therapy, not randomized, etc.). Of the remaining 127 papers, 21 concerned adjuvant therapy (13 of which met criteria and were included in our 2002 review). Articles were excluded from this report as follows: 19 contained preliminary data only (no significant information regarding survival), nine were not randomized, nine involved patients with surgically resectable disease, one involved supportive-care interventions only, one involved commentary on previously published data and five involved diseases other than HCC.
Eighteen articles investigating hepatic artery embolization-based therapy met criteria for review. Of these randomized trials, 12 were from Asian centers (People's Republic of China n = 5, Japan n = 4, Hong Kong n = 2, Taiwan n = 1) and six studies were from Europe (France n = 3, Spain n = 2, Greece n = 1). A significant survival benefit was reported in 33% (six of 18), and an additional two studies reported results and survival benefit in patient subsets only. Four studies randomized over 200 patients, two involved 100-200 subjects, nine involved 50-100 subjects and three trials randomized fewer than 50 patients. In seven of the 18 trials, sample size was based on statistical power. Side-effects were graded in one study; 11 studies provided detailed description and five studies provided limited discussion of side-effects.
Chemoembolization versus supportive care or non-beneficial systemic therapy
Seven studies involving 546 patients compared chemoembolization to supportive care or systemic therapy not currently associated with clinical benefit (two trials). The number of embolizations varied (the mean number of treatments ranged from 1 to 4.5 in the different trials). Enrollment occurred between 1984 and 2000. Five of the studies were European (France and Spain) and two were Asian (Taiwan and Hong Kong). The majority of European subjects had either HCV or alcohol-related cirrhosis. Asian patients were predominantly infected with HBV. The more-recently published studies have tended to include healthier subjects (Child-Pugh class A or B liver dysfunction) and those with more limited tumor extent. Four trials enrolled subjects from a single center; three were multicenter (see Table 1 ).
Specific studies
During the 1980s, Lin et al. conducted a three-arm trial of hepatic arterial embolization (TAE) involving 63 Taiwanese patients [15] . Eighty percent of patients were HBVinfected; the extent of liver dysfunction was not stated. One arm involved monthly TAE (mean of 2.1 treatments per patient). A second group received a single TAE followed by monthly high-dose 5-flourouracil (5-FU; 1 g/m 2 Â 5 days, with a mean of 3.1 treatments per patient). A third arm received monthly 5-FU only (mean of 2.8 treatments per patient). One-year survival for the group receiving ongoing TAE was superior to those receiving TAE/5-FU or 5-FU only [42, 21 and 13% respectively; the difference between the ongoing-TAE arm and the 5-FU-only arm was considered statistically significant (p < 0.01)]. Two-year survival was 25, 21 and 13%, respectively; these differences did not achieve significance. Three patients suffered major, non-fatal embolization-related complications (cholecystitis and gastric ulcer). There was no hepatic failure or abscess formation in any patient following TAE. Pain and fever occurred in over 50% of patients. In 1990, Pelletier et al. reported results of a multiinstitutional study [16] . Forty-two patients (predominantly with alcohol-induced liver disease) were randomized to receive either chemoembolization (including doxorubicin) or conservative management. Chemoembolization was repeated 2, 6 and 12 months following the initial treatment. The mean number of treatments per patient was 2. Fifty percent of the patients had evidence of liver decompensation (ascites) upon entry and had tumor involving over one-third of total liver volume.
Although an objective tumor response was seen in 33% of patients in the TACE group, there was no difference in survival (24 and 31% at 1 year, respectively). Chemoembolization-related side-effects included hepatitis, acute renal failure and gastrointestinal hemorrhage. Pain and fever were also common.
Between 1990 and 1992, the French Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire conducted a randomized trial involving 24 institutions comparing TACE to conservative management [17] . Chemoembolization included cisplatin and lipiodol, and was repeated at 2-month intervals (mean of 2.9 treatments). Although many patients had well-compensated liver function (100% Child-Pugh Class A liver function; 90% Okuda Stage I), 13% of subjects had diffuse tumor and nearly one-half had multifocal disease. Patients assigned to the control group had a higher rate of portal vein thrombosis (PVT) than the TACE group (13 versus 2%, respectively) and a higher tumor burden (greater than 50% liver volume) than the TACE group (15 versus 6%, respectively). The trial was stopped after a scheduled analysis failed to demonstrate a 50% increase in survival at 8 months. There was a trend towards decreased death (RR 1.4, CI 0.9-2.2) in the chemoembolization arm. Hospitalization was more frequent in the TACE group. Sixty percent of the 50 patients who underwent chemoembolization developed liver failure, defined as encephalopathy, ascites or bilirubin elevation. Eighty-six percent of the chemoembolization patients developed abdominal pain, fever or vomiting.
The lack of survival benefit despite significant tumor response led investigators to modify approaches in subsequent trials; these included more restrictions on tumor extent and liver dysfunction, and continued variations concerning use of chemotherapeutic agents (including lipiodol), and frequency and intensity of embolization.
Bruix et al. conducted a randomized trial comparing embolization (without chemotherapy) versus symptomatic treatment [18] . Most of the 80 subjects had HCVrelated liver disease and Child-Pugh Class A liver function. Forty patients received TAE with gelatin cubes; additionally, for those with unilobar HCC, a metal coil was placed to induce complete arterial occlusion. Most patients (60%) received a single embolization. Despite a 55% partial response rate, there was no difference in 2year survival (50% for the treatment group, 49% for the control arm). The authors noted an unexpectedly high survival in the control arm (27% were alive at 4 years). Embolization was well tolerated and there was no difference in complications such as ascites, variceal bleeding, bacterial infection, encephalopathy or need for hospitalization. Performance status was similar in both groups at baseline and 2 years after treatment.
Pelletier et al. randomized 73 patients to receive ongoing TACE and oral tamoxifen versus tamoxifen alone [19] .
Chemoembolization included cisplatin and lipiodol in addition to gelatin sponge particles; TACE was planned every 3 months during the first year and every 4 months subsequently. Patients underwent a median of three treatments. Most patients had alcohol-induced liver disease and Child-Pugh Class A liver function. Fever and abdominal pain were the most common side-effects of TACE. Liver decompensation occurred in 50% of the patients on the embolization arm. Embolization was associated with two fatalities (acute liver failure and gastric perforation). Side-effects of tamoxifen were not described. There was no difference in 1-year survival between the TACE and tamoxifen arms (51 and 55%, respectively).
Many of the studies discussed above were powered to demonstrate only large differences in survival and hence pooled analyses were attempted. However, authors providing review and meta-analyses of these studies arrived at disparate conclusions. . Although there has been significant speculation regarding intrinsic differences between HCC in European versus Asian populations, and between HCV-and HBV-infected patients, these potential differences have never been demonstrated conclusively in a prospective setting, and may be related to factors such as liver function and stageat-presentation. It is worth noting that Lo's study included patients with invasion of portal vein branches (these patients were excluded from the Barcelona study) and that median tumor size was larger in this trial [7 cm (range of 4-14) versus 5 cm (range 3.9-6)] than in the Barcelona group's patients.
A recent meta-analysis incorporating data from the above seven trials also suggested a survival benefit conferred by hepatic arterial chemoembolization [9] . In this paper, Llovet and Bruix conclude that chemoembolization is associated with reduced risk of death at 2 years with an odds ratio ranging from 0.42 to 0.53, depending upon which trials are included in the assessment.
Conclusion
The more recently published trials provide more conclusive evidence that arterial embolization confers benefit in carefully selected patients with unresectable HCC. Chemoembolization (utilizing cisplatin and doxorubicin) may be more effective than embolization without antineoplastic agents. Patient selection is critical; the studies demonstrating robust benefit to therapy involved predominantly patients with well-preserved liver function and tumors which were neither diffuse nor involving extensive portions of liver volume. Advances in supportive care likely also have contributed to more successful outcomes with anticancer therapy in recent years. Optimal treatment schedule remains uncertain, although the studies by Llovet and Lo (mean number of treatments 2.9 and 4.8, respectively) suggest that ongoing therapy is often essential.
Hepatic artery chemoembolization utilizing different chemotherapy agents
Several groups have attempted to ascertain whether the addition of chemotherapy to embolization enhances survival. Five studies involving 1301 patients investigated different chemotherapeutic agents as components of hepatic chemoembolization. All five trials took place in Asia. Three were conducted in Tokyo or environs by the multi-institutional Cooperative Group for Liver Cancer in Japan (CGLCJ). Enrollment occurred between 1988 and 2000 (see Table 2 ).
Specific studies
In 1992, Kawai et al. reported on the Japanese Cooperative Group's initial data [22] . Their study evaluated the benefit of intra-arterial doxorubicin (40 mg/m 2 ) as a component of TAE. In total, 289 patients from 175 institutions with predominantly Child's A liver function were randomized to receive transcatheter arterial embolization (TAE) including lipiodol with or without doxorubicin (40 mg/m 2 ). Thirty-seven percent of patients received a second embolization and 19% had subsequent hepatic resection. 
Conclusion
With regard to chemoembolization-based therapy in HCC, there is no clear evidence to suggest optimal chemotherapeutic agents nor their dosages. Doxorubicin may confer superior antitumor effect (relative to farmorubicin), but its impact on long-term survival is unlikely to be significant. Higher doses of lipiodol may confer a survival benefit in patients with Child-Pugh Class A liver function. Unfortunately, these studies did not incorporate statistical power into their design. Reporting of untoward effects, duration of actual treatment and duration of follow-up was also incomplete.
Hepatic artery embolization versus hepatic artery chemotherapy
We identified two studies that compared chemoembolization to hepatic artery chemotherapy without embolization (see Table 3 ). Lu et al. randomized 52 subjects to receive either TACE (including lipiodol) or arterial chemotherapy and lipiodol without embolization [28] . Patients were categorized as type I (defined as Child-Pugh Class A and B liver function) or type II (Child-Pugh Class C or portal vein invasion or diffuse hepatic tumor). Survival was reported by subset analysis only. Two-year survival for type I (low-risk) patients was 40% for those receiving chemoembolization and 47% for those receiving arterial chemotherapy/lipiodol without embolization; these differences were not statistically significant. For type II (high-risk) patients, 1-and 2-year survival rates for the embolization group were 7 and 0%, respectively; 1-and 2-year survival for the lipiodol-chemotherapy group were 28 and 14%, respectively (p < 0.05).
In 1995, Hatanaka et al. conducted a three-arm trial comparing hepatic chemoembolization (with and without lipiodol) to hepatic artery chemotherapy [29] . Between 1986 and 1991, 429 patients were enrolled and 272 received randomized therapy. Reported results were difficult to interpret because patients who elected to receive subsequent therapies off-protocol were excluded from analysis; additional patients with advanced disease receiving hepatic chemotherapy without randomization were also discussed. Nonetheless, 60 randomized patients received TACE (including cisplatin, doxorubicin and FUDR), 78 underwent TACE (including lipiodol and chemotherapy as above) and 134 received hepatic artery lipiodol and chemotherapy (as above) without embolization. Mean number of treatments per patient ranged between 2.3 and 2.8 (depending upon treatment arm). One-, 2-, 3-and 5-year survival rates for those receiving TACE without lipiodol were 80, 65, 49 and 28%, respectively. Survival for those receiving TACE including lipiodol was 86, 55, 35 and 26% at 1, 2, 3 and 5 years. Differences between theses arms were not statistically significant. Survival for those receiving chemotherapy and lipiodol (without embolization) at 1, 2, 3 and 5 years was 66, 50, 36 and 18%. Survival on this arm was statistically inferior relative to the groups receiving embolization as a component of therapy.
Conclusion
The limited number of interventions comparing arterial embolization to non-embolization-based locoregional therapy prevents definitive conclusion. In patients with less advanced disease, embolization (with or without additional agents) likely is more effective than hepatic artery chemotherapy (including lipiodol) without embolization. This was demonstrated in the Japanese trial, in which nearly one-half of patients had unifocal (solitary) HCC at presentation. As demonstrated by Lu et al.'s results, embolization is unlikely to confer benefit (and is likely deleterious) in patients with advanced tumor (including portal venous invasion) and in patients with marked hepatic dysfunction [28] .
Hepatic artery embolization utilizing different technical embolization methods
In 1998, Zheng et al. evaluated the effect of a Chinese herb comprised of starch mucagel and a volatile oil known as bletilla striata as a vascular embolizing agent [30] . Fifty-six patients undergoing hepatic artery embolization were treated with bletilla striata and 50 patients were treated with the more widely utilized gelfoam particles. The authors found a more significant decrease in AFP and tumor shrinkage in the group receiving the medicinal herb. Treatment was also better tolerated and was given for a longer duration (7 months). Survival at 1, 2 and 3 years for the bletilla group was 82, 45 and 34% versus 49, 31 and 16% for those embolized with gelfoam; this difference was statistically significant. Toxicity was reportedly similar between the embolization methods. However, the authors cautioned that safe use of bletilla striata embolization requires highly selective arterial catheterization; further explanation was not provided.
Kwok et al. investigated the use of autologous blood clot as an embolizing agent [31] . One hundred patients with Child-Pugh Class A or B liver function were randomized. Fifty-two patients received TACE via autologous clot every 6 weeks. Forty-eight patients received the TACE with the more commonly utilized gelfoam. There was no difference in survival. Side-effects were similar in both groups, and included frequent fever, vomiting and abdominal pain.
Conclusion
Very little randomized data exists regarding optimal physical means of hepatic arterial embolization. The studies above suggest that alternate mechanisms are feasible and at times may result in therapeutic differences (see Table 4 ). There is no evidence-based consensus regarding ideal physical agents for embolization-based therapy in HCC.
Hepatic artery-based therapy with or without local immunotherapy
In 1991, Tang et al. evaluated hepatic artery chemotherapy and low-dose external bean radiotherapy with addition of a bacterial vaccine (MBV) derived from Streptococcus pyogenes and Serratia marcescens [32] . In this study, 48 patients were randomized to receive intraarterial cisplatin and radiotherapy with or without MBV via a surgically implanted hepatic artery catheter. The vaccine was infused daily or every other day through the hepatic arterial catheter. Regional radiotherapy was also given on days 1, 2 and 3, and alternated with arterial cisplatin (20 mg/day) on days 8, 9 and 10. This cycle was usually repeated 2-4 times. Survival at 1, 2 and 3 years was 59, 41 and 41% for the MBV group, and 39, 25 and 20% for the controls, respectively (p = 0.01, p = 0.09 and p = 0.07). Side-effects included transient chills and fevers immediately following the MBV injection. An analysis of macrophage activity in those receiving the MBV injection increased, but was not statistically different from those who did not receive the injection. The authors concluded that they considered MBV a potentially useful treatment.
In 1997, Lydigakis et al. compared hepatic artery chemoembolization including interferon (IFN)-g and interleukin (IL)-2 to hepatic artery chemoembolization alone [33] . In total, 193 predominantly Greek patients considered ineligible for surgical resection were randomized. Ninety-one patients received hepatic artery chemoembolization (including lipiodol, mitomycin, carboplatin and mitoxantrone) and 102 patients received similar therapy with the addition of IL-2 and IFN-g via two arterial catheters inserted into the splenic and hepatic arteries. Treatment was continued every month for the first year and every 2 months for the subsequent years. All patients had tumor involving over one-half of the liver volume. Overall survival was significantly improved in the group receiving immunotherapy (22.3 versus 10.2 months, reported as mean survival). Sideeffects were described as minimal. The authors noted an improvement in cytopenias and esophageal varices for those patients in whom splenic artery infusion resulted in arterial occlusion, although specific results for this were not quantified.
An additional study by Chung et al. in which the addition of s.c. IFN-a to hepatic artery cisplatin resulted in a survival benefit (versus cisplatin alone and versus supportive therapy) is discussed in Part II of this report [34] .
The addition of immunotherapy to hepatic artery-based treatments may confer a survival benefit; the small number of trials precludes definitive assessment (see Table 5 ). Trials utilizing immunotherapies (including activated lymphocyte infusions, interferons and addition Table 3 Hepatic artery embolization versus hepatic artery chemotherapy of interferons to hepatic arterial therapy) have been associated with benefit in the adjuvant setting [35] [36] [37] . Additional investigations will hopefully clarify the role of such therapies in conjunction with hepatic arterial therapy in unresectable HCC.
Overall conclusions regarding hepatic arterial embolization-based therapies in HCC with respect to the randomized literature (i) Chemoembolization for unresectable HCC confers a significant survival benefit. Patients for whom TACE is likely to be helpful are those with relatively preserved hepatic function (i.e. Child-Pugh Class A and selected Child-Pugh Class B liver dysfunction), modest tumor burden (i.e. absence of portal vein invasion, solitary or otherwise limited nodular or encapsulated tumors) and preserved performance status. (ii) The positive results of the recently reported trials suggest that chemoembolization (TACE) may confer a more significant benefit than embolization without iodized oils or anticancer agents (TAE), although the number of trials in which these therapies have been compared is limited. (iii) Embolization is potentially harmful in patients with portal vein thrombosis (invasion), Child-Pugh Class C liver dysfunction or diffuse tumor, especially if HCC is involving a majority of the liver volume.
Patients with these disease characteristics may be considered for arterial therapy without embolization; studies investigating such approaches are discussed in Part II of this review. (iv) Embolization-based therapy appears to confer greater benefit than hepatic artery infusion of anticancer drugs or lipiodol without embolization (at least in patients with relatively limited tumor and preserved hepatic function), although very few investigators have prospectively studied this question. (v) Recent studies in which chemoembolization was associated with a survival benefit employed sequential treatments, and utilized combinations of lipiodol and either cisplatin or doxorubicin. (vi) There is limited information regarding optimal material for embolization, schedules of treatment and chemotherapy doses. No randomized trials have prospectively tested the utility of different types or sizes of embolization particles; there is no literature regarding the optimal degree of vascular occlusion required for safe and efficacious embolization. (vii) Addition of immunotherapy to hepatic artery-based treatments has demonstrated potential for enhanced efficacy in a small number of studies; this represents a promising direction for future investigations.
